By Daniel Borkert, FNP-C
Last reviewed October 23, 2026. Checked against the sources named below on October 23, 2026.
Pharmacology is the section students say they fear most, and it is rarely the section that beats them on facts. It beats them on volume. Hundreds of drugs, one exam, and a study method that treats every drug as a separate fact to memorize. That method fails because the boards do not test hundreds of drugs. They test a few dozen classes, and inside each class they test the same four things, the mechanism of action, the patients at risk, the monitoring it needs, and the interactions that matter. Learn a class by those four questions and most of its drugs answer themselves.
This sheet is built on that pattern. Every entry carries the mechanism in miniature, because a mechanism remembered is a dozen facts recovered under pressure. A fact with no mechanism under it is the first thing stress erases.
In this guide
- The short answer
- Your pharmacology dump sheet, what to write in the first minute
- Why the safety column is written the way it is
- Drug classes the boards keep coming back to
- Deprescribing, the quiet theme under half these questions
- Mnemonics and memory hooks, used honestly
- Frequently asked questions
- Sources for this page
The short answer
This is a one sheet pharmacology reference for the FNP boards, organized by drug class and written for outpatient primary care prescribing, the setting the FNP exam tests. Each class gets its name pattern, its mechanism in one line, where it is used, the safety points and red flags the boards return to, and the monitoring that keeps it safe. At the top sits the dump sheet panel, the small set of numbers and antidotes worth writing on the exam scratch sheet in the first minute. The sheet is a compression of the pharmacology the boards actually test at FNP depth. It is a study tool, not a prescribing reference, and memorizing it alone is not a study plan. To test the facts on this sheet against patients, work the companion pharmacology practice questions and timed quiz.
Want this sheet as a printable PDF? Join the free student list and the pharmacology cheat sheet will be emailed to you, plus a short sequence of study emails over the following two weeks.
Your pharmacology dump sheet, what to write in the first minute
Candidates get a scratch sheet at the exam. The first minute is free, and the best use of it is writing down the small set of numbers that pharmacology questions keep asking for, before the first question has a chance to crowd them out. Write these.
| Write this | Why it earns its place |
|---|---|
| INR 2.0 to 3.0 | The warfarin target for atrial fibrillation and most venous thromboembolism (DVT and PE), the range half of anticoagulation questions are built on |
| Metformin, stop under 30, do not start 30 to 45, cap 1,000 mg in between | The eGFR rules, asked in some form on nearly every exam cycle |
| 36 hours | The washout between the last ACE inhibitor dose and the first sacubitril-valsartan dose, skipped only when the switch is from an ARB |
| 4 to 12 weeks | The lipid panel recheck after a statin starts or its dose changes, then every 6 to 12 months thereafter |
| TSH over 10, consider treatment; under 10, decide | Subclinical hypothyroidism in one line, treatment should be considered above 10 mIU/L and is individualized below it |
| Urate under 6 | The allopurinol target in gout, titrated from a low start |
| Apixaban 2.5, two of three | For stroke prevention in nonvalvular atrial fibrillation, the reduced dose needs two of age 80 or older, weight 60 kg or less, creatinine 1.5 mg/dL or higher |
| Gout flare, colchicine 1.2 then 0.6 | The low dose regimen for an acute flare, one dose and a half dose an hour later, as effective as the old high dose schedules with far less harm |
| TSH recheck, 6 to 8 weeks | The interval after any levothyroxine dose change before the level means anything |
| Lithium, about 0.8 to 1.0 maintenance | The maintenance target on the FDA label, with toxicity risk climbing above 1.5 mEq/L |
| Naloxone, opioids. Vitamin K, warfarin. Digoxin immune fab, digoxin. N-acetylcysteine, acetaminophen. Protamine, heparin. Glucagon, beta blockers | The antidote pairs, the fastest free points in pharmacology |
One warning belongs on the dump sheet itself. Flumazenil, the benzodiazepine reversal agent, is the antidote the boards use as a trap. Its label carries a boxed warning for seizures, most often in patients on long term benzodiazepines or with cyclic antidepressant poisoning, so in a patient with either risk it is withheld rather than given. If a question offers it as the easy reversal, read the patient again.
Why the safety column is written the way it is
Every class table below gives the safety points as much room as the uses, and that is deliberate. Board pharmacology questions are rarely “what does this drug do.” They are “this patient, on this drug, now has this problem,” and the problem is almost always in the safety column, the adverse effect with a mechanism, the interaction with a pathway, the lab nobody checked.
Two checks carry most of that weight. Renal function is checked before a renally cleared drug is prescribed, whether it is a bisphosphonate, an SGLT2 inhibitor, or an anticoagulant. Warfarin gets a fresh INR check whenever an antibiotic that can move the INR is started beside it.
Drug classes the boards keep coming back to
Read the name pattern first. Drug stems are the cheapest points in pharmacology, because a stem names the class, and the class answers the mechanism question before you have finished reading the question stem. One refinement matters. The statin stem is properly -vastatin, and the -dipine stem belongs to the dihydropyridine calcium channel blockers only, amlodipine and nifedipine and their family. Diltiazem and verapamil are calcium channel blockers too, but they do not carry the stem and they act on the heart rate in a way the dihydropyridines do not.
Blood pressure
| Class and stem | Mechanism in miniature | Where it is used | Safety points and red flags | Monitoring |
|---|---|---|---|---|
| ACE inhibitors, -pril | Block the conversion of angiotensin I to angiotensin II, and slow bradykinin breakdown, which is both part of the benefit and the cause of the cough | First line for hypertension, and protective in diabetes with albuminuria and in heart failure | Dry cough from bradykinin, switch to an ARB rather than treating the cough. Angioedema is the rare emergency. Raises potassium and creatinine. Never in pregnancy | Basic metabolic panel 2 to 4 weeks after starting or raising the dose. A creatinine rise up to 30 percent from baseline is generally acceptable |
| ARBs, -sartan | Block the angiotensin II receptor directly, leaving bradykinin alone, which is why cough is rare | The substitute when an ACE inhibitor is not tolerated, with the same kidney and heart indications | Same potassium, creatinine, and pregnancy cautions as ACE inhibitors, without the cough. Do not combine with an ACE inhibitor | Same basic metabolic panel schedule as ACE inhibitors |
| Thiazide diuretics | Block sodium reabsorption in the distal tubule, lowering volume and then vascular resistance | First line for hypertension, often the drug added when one agent is not enough | Low potassium and low sodium are the classic traps, along with raised uric acid in gout and raised glucose | Basic metabolic panel, and uric acid where gout is in the picture |
| Calcium channel blockers, -dipine | Relax arterial smooth muscle by blocking calcium entry, the dihydropyridines acting on vessels far more than on the heart | First line for hypertension, and a standard add on agent | Dose-related ankle edema is the signature effect, more drug effect than fluid overload. Constipation belongs mostly to verapamil, outside this stem | Blood pressure and a look at the ankles |
| Beta blockers, -olol | Block beta adrenergic receptors, slowing the heart and lowering renin release | Not first line for uncomplicated hypertension on their own. Their home is after myocardial infarction, in heart failure, and in rate control | Mask the warning symptoms of hypoglycemia, a real issue in diabetes. Bronchospasm risk in reactive airways. Never stop abruptly after long use | Heart rate and blood pressure, glucose awareness in diabetes |
Lipids
| Class and stem | Mechanism in miniature | Where it is used | Safety points and red flags | Monitoring |
|---|---|---|---|---|
| Statins, -vastatin | Block HMG-CoA reductase, the rate limiting step in cholesterol production, which makes the liver pull more LDL out of the blood | The foundation of lipid treatment and ASCVD risk reduction | Muscle symptoms are the common complaint. High intensity means atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, lowering LDL by about half or more. Moderate intensity lowers it by about 30 to 49 percent | Lipid panel 4 to 12 weeks after starting or changing dose, then every 6 to 12 months |
| Ezetimibe and PCSK9 agents | Ezetimibe blocks cholesterol absorption in the gut. PCSK9 agents keep more LDL receptors alive on the liver cell surface | Added when LDL-C stays above goal on a maximally tolerated statin. The 2026 guideline goals are under 100 mg/dL for borderline and intermediate risk primary prevention, under 70 for high risk primary prevention and most established ASCVD, and under 55 for very high risk ASCVD. The add on, ezetimibe, a PCSK9 agent, or bempedoic acid, is chosen by the size of the remaining gap | Both are notably well tolerated next to the drugs they follow, which is why they are the add ons rather than the foundation | Lipid panel on the same schedule as the statin |
Diabetes
| Class and stem | Mechanism in miniature | Where it is used | Safety points and red flags | Monitoring |
|---|---|---|---|---|
| Metformin | Lowers hepatic glucose production and improves insulin sensitivity, without driving insulin secretion, which is why it does not cause hypoglycemia on its own | First line for type 2 diabetes in most patients | The kidney rules are the testable core. Contraindicated below an eGFR of 30. Starting it between 30 and 45 is not recommended. A patient already on it in that band is capped at about 1000 mg a day with close monitoring. Hold it in acute illness that threatens the kidneys, because the feared harm is lactic acidosis | eGFR at least yearly and more often as it falls, vitamin B12 over time |
| Sulfonylureas | Force the pancreatic beta cell to release insulin whether glucose is high or not, which explains both the benefit and the harm | Older low cost agents, used less as safer options have spread | Hypoglycemia and weight gain are the class price. Glyburide, with its long half life, carries the highest hypoglycemia risk and is a poor fit for older adults | A1C, and honest questions about hypoglycemia episodes |
| SGLT2 inhibitors, -gliflozin | Block glucose reabsorption in the proximal tubule, so glucose leaves in the urine, along with a modest sodium and volume effect | Type 2 diabetes, and independently in heart failure and chronic kidney disease, where the outcome benefits are the reason they are prescribed | Genital yeast infections are the common harm, from the glucose rich urine. Euglycemic ketoacidosis is the rare dangerous one, serious illness on a normal glucose reading. Pioglitazone is the contrast drug here, a different class entirely. It causes fluid retention, is not recommended in symptomatic heart failure, and starting it in NYHA class III or IV heart failure is contraindicated | eGFR and volume status, foot and skin checks in kidney disease |
| GLP-1 receptor agonists, -glutide | Mimic the incretin hormone, raising insulin only when glucose is high, slowing gastric emptying, and reducing appetite | Type 2 diabetes, especially with cardiovascular disease or where weight loss is a goal | Nausea and vomiting are the common effects. Contraindicated with a personal or family history of medullary thyroid cancer or MEN 2. The slowed stomach matters before surgery and in gastroparesis | A1C and weight, gastrointestinal tolerance |
| DPP-4 inhibitors, -gliptin | Slow the breakdown of the body’s own incretins, a gentler version of the GLP-1 idea | A well tolerated option where hypoglycemia must be avoided | Weight neutral and hypoglycemia free on their own, with no heart failure outcome benefit. Saxagliptin is the exception that increased heart failure hospitalizations in its outcomes trial | A1C, kidney dose adjustments for most of the class |
Blood thinners and the heart failure core
| Class | Mechanism in miniature | Where it is used | Safety points and red flags | Monitoring |
|---|---|---|---|---|
| Warfarin | Blocks the recycling of vitamin K, so the liver cannot activate clotting factors II, VII, IX, and X | Atrial fibrillation and venous thromboembolism where a DOAC is not suitable, and mechanical heart valves, where it is the only option | Nearly everything interacts with it, antibiotics, diet changes, and new supplements among them. The target INR for atrial fibrillation is 2.0 to 3.0. A high INR without bleeding is managed by holding doses, not by reflex reversal | INR on schedule, and an interaction check before any new drug is started beside it |
| DOACs, apixaban the prototype | Directly inhibit factor Xa, a single point in the clotting cascade, which is why the dose is fixed rather than titrated to a blood level | First choice for most atrial fibrillation and venous thromboembolism | Bleeding risk climbs when an NSAID is added, and the first fix for minor bleeding is removing the NSAID, not stopping the anticoagulant. The reduced apixaban dose, 2.5 mg twice daily, applies to stroke prevention in nonvalvular atrial fibrillation and needs two of the three dose reduction criteria on the dump sheet | Kidney function and hemoglobin, and a medication list review at every visit |
| The heart failure four pillars | Four classes, each blocking a different arm of the neurohormonal response that drives heart failure progression | Patients with symptomatic heart failure with reduced ejection fraction should be offered all four | ARNI or ACE inhibitor or ARB, an evidence based beta blocker, metoprolol succinate, carvedilol, or bisoprolol, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. The ARNI switch carries the 36 hour ACE inhibitor washout from the dump sheet | Potassium and creatinine whenever the renin angiotensin arm or the MRA changes |
| Digoxin | Raises the force of contraction and slows conduction through the AV node, an old drug with a narrow window | An add on in heart failure and a rate control option, well behind the four pillars | Toxicity is nausea, visual changes, and confusion, and low potassium makes the heart sensitive to it even at normal levels. Digoxin immune fab is the antidote for serious toxicity | Level, potassium, magnesium, and kidney function |
Antibiotics, the outpatient set
| Drug | Mechanism in miniature | Where it is used | Safety points and red flags | Monitoring |
|---|---|---|---|---|
| Amoxicillin and penicillins | Block bacterial cell wall synthesis, bactericidal | First line for group A streptococcal pharyngitis, a full 10 day course, because Streptococcus pyogenes has never developed penicillin resistance. Macrolides are the reserve for true penicillin allergy, never the default | Allergy history is the work. A vague childhood rash and a true anaphylaxis history lead to different drugs | Clinical response in 48 to 72 hours |
| Doxycycline | Blocks bacterial protein synthesis at the 30S ribosome | Community respiratory infections, tick borne illness, acne, and atypical coverage | Photosensitivity and pill esophagitis are its signatures. Take it upright with a full glass of water and food | Sun protection counseling is part of the prescription |
| TMP-SMX | Blocks two steps of bacterial folate synthesis in sequence | Urinary tract infection and skin infection where local resistance allows | Raises potassium, trimethoprim behaves a little like a potassium-sparing diuretic, and it raises the INR in patients on warfarin. It also raises digoxin levels, especially in older adults | Potassium and creatinine on longer courses, INR when warfarin is aboard |
| Nitrofurantoin | Damages bacterial DNA and ribosomes by several routes at once | Uncomplicated cystitis only | It never reaches kidney tissue levels, so it does not treat pyelonephritis, and it is avoided when the eGFR falls below 30 | Urine culture where the picture is not simple |
| Fluoroquinolones | Block bacterial DNA gyrase and topoisomerase, broad and powerful | Reserved agents in outpatient practice, not first line for simple infections | The FDA boxed warning covers tendon rupture and tendonitis. Aortic aneurysm and dissection risk sits in the label’s warnings as well. Add QT prolongation and blood sugar swings | The monitoring is restraint, use them where the benefit earns the risk |
| Oral vancomycin and fidaxomicin | Poorly absorbed from the gut, which is the point, they act inside the colon | Clostridioides difficile infection. Fidaxomicin is the guideline preferred first agent for a first episode, oral vancomycin 125 mg four times daily for 10 days is the practical standard where fidaxomicin is out of reach. Metronidazole is no longer first line for any episode | Antimotility drugs such as loperamide are avoided in acute infection, they can set up toxic megacolon | Stool frequency and hydration, recurrence watch for weeks after |
Thyroid, mood, gout, steroids, and lithium
| Class | Mechanism in miniature | Where it is used | Safety points and red flags | Monitoring |
|---|---|---|---|---|
| Levothyroxine | Replaces the thyroid hormone the gland no longer makes | Hypothyroidism, overt and the subclinical cases that meet the treat threshold | Absorption is fragile. Empty stomach, 30 to 60 minutes before eating, and about 4 hours away from iron and calcium. Recheck the TSH 6 to 8 weeks after any dose change, earlier readings mislead | TSH on the 6 to 8 week cycle until stable, then yearly |
| Methimazole | Blocks new thyroid hormone synthesis | Graves disease and other hyperthyroidism | Fever or a severe sore throat on methimazole is agranulocytosis until proven otherwise. Stop the drug at once and get an urgent CBC. After confirmed agranulocytosis the drug is never restarted | Baseline CBC and liver tests, and the fever warning given to every patient in plain words |
| SSRIs and their neighbors | Raise serotonin signaling, the SSRI arm directly, bupropion by norepinephrine and dopamine, mirtazapine by blocking the receptors that cause its sedation and appetite effects | Depression and anxiety, first line in primary care | Older adults can develop SIADH and hyponatremia, new confusion on an SSRI earns a sodium check before it earns a dementia label. Serotonin syndrome is the combination risk, triptans, MAO inhibitors, and linezolid among the partners. Paroxetine and venlafaxine punish abrupt stops with discontinuation symptoms. Bupropion lowers the seizure threshold and is contraindicated in eating disorders. Mirtazapine sedates and adds weight, sometimes exactly what a frail patient needs | Sodium in older adults after starting, mood and PHQ-9 trend, a bipolar screen before the first prescription |
| Allopurinol and colchicine | Allopurinol blocks xanthine oxidase, lowering uric acid production. Colchicine disrupts the microtubules neutrophils need to swarm a joint | Allopurinol is the long term gout control. Colchicine is the early flare drug at the low dose on the dump sheet | Start allopurinol low, 100 mg a day or less, lower in kidney disease, and titrate every few weeks to a urate under 6. Screen for HLA-B*58:01 before starting in patients of Southeast Asian or African American descent, where the severe skin reaction risk concentrates. Colchicine interacts with clarithromycin, which blocks its CYP3A4 and P-glycoprotein exit routes, and the interaction in a patient with kidney disease can be lethal | Urate to target, kidney function, and an interaction check before any macrolide is prescribed beside colchicine |
| Glucocorticoids | Suppress inflammation and the immune response broadly, and suppress the body’s own cortisol axis while they do it | Flares of inflammatory disease, severe allergic and pulmonary episodes, replacement in adrenal failure | Courses beyond about 3 to 4 weeks can suppress the HPA axis and should not be stopped abruptly. The patient who stops a long course abruptly and then gets sick can land in adrenal crisis, refractory shock in a patient who cannot mount a cortisol response. Raise glucose, pressure, and infection risk while aboard | Taper plan written into the prescription, glucose and pressure on longer courses |
| Lithium | Narrows the swing of mood signaling by mechanisms still argued about, cleared almost entirely by the kidney | Bipolar maintenance, a psychiatry partnered drug that primary care monitors constantly | The window is narrow, about 0.8 to 1.0 mEq/L for maintenance on the FDA label, with toxicity climbing above 1.5. Guideline maintenance targets run lower than the label, down to 0.6 mEq/L, so the 0.6 to 1.2 mEq/L band taught for the boards joins that floor to the acute ceiling rather than contradicting the label. Baseline before starting is a BMP, a TSH, and a pregnancy test. NSAIDs and thiazide diuretics raise its level, and dehydration is the usual trigger of toxicity, coarse tremor, confusion, and unsteady gait | Level, BMP, and TSH on schedule, and a level recheck whenever an interacting drug starts or stops |
Deprescribing, the quiet theme under half these questions
Read the tables again and a pattern shows. A large share of board pharmacology is not about starting drugs. It is about the drug that should never have been combined, the dose that should have followed the kidney down, the agent that should have been stopped before the new one started. The exam tests the medication list as much as the diagnosis.
My own process starts with the patient. I look at where the patient is, and at their prognosis, then weigh the risks, benefits, and alternatives of each medication, including the interactions between them. I always want to try to reduce the number of medications when I can. The primary factor, though, is shared decision making with the patient. Sometimes I cannot in good conscience continue prescribing a medication, but I usually try to reach a shared decision with the patient first.
Mnemonics and memory hooks, used honestly
Many readers arrive here from a search for pharmacology mnemonics, so this section answers that search straight. A mnemonic is a recall aid laid on top of a mechanism, and it works only in that order. A student who can recite a clever phrase for the anticholinergic toxidrome but cannot say what atropine does at a muscarinic receptor owns the decoration and not the knowledge. The exam writes questions that punish exactly that gap.
Used in the right order, hooks help. Three kinds earn their place on this sheet.
First, the rules that are already short enough to memorize as rules. Two of three for the apixaban dose. Thirty six hours for the ARNI washout. Four to twelve weeks for the statin recheck. These are not mnemonics, they are the dump sheet, and they pay out on every exam.
Second, the classic toxidrome rhyme for anticholinergic poisoning, blind as a bat, dry as a bone, red as a beet, mad as a hatter, hot as a hare. It survives because each phrase is a receptor fact in costume, blocked muscarinic receptors in the eye, the glands, the skin vessels, the brain, and the sweat glands.
Third, class stems, the built in mnemonics the drug names already carry. A stem is a hook that can never be forgotten at the moment it is needed, because the question itself supplies it.
Frequently asked questions
What should go on an FNP pharmacology dump sheet?
The numbers a candidate cannot afford to derive under time pressure. The warfarin INR range, the metformin kidney rules, the 36 hour ARNI washout, the statin recheck interval, the subclinical hypothyroid treatment threshold, the gout urate target, the apixaban two of three rule, the low dose colchicine regimen, the levothyroxine recheck interval, the lithium maintenance range, and the antidote pairs. The panel at the top of this page is the list, written the way it should be written in the first minute of the exam.
Are mnemonics enough for pharmacology on the boards?
No. They are a recall aid on top of mechanism, useful for lists and toxidromes, and useless for the questions the boards actually ask, which put a patient on a drug and ask what happens next. Those questions are answered by the mechanism, the safety column, and the monitoring, which is why every entry on this sheet carries its mechanism in miniature.
Is this sheet a substitute for practice questions?
No, and the order matters. Facts first, then questions, because questions are where facts get tested against a patient.
Sources for this page
American Family Physician topic reviews and guideline summaries, including its hypertension treatment review, its cholesterol guideline summaries, with the lipid entries on this sheet refreshed against the 2026 ACC/AHA dyslipidemia guideline, its type 2 diabetes noninsulin pharmacotherapy review, its practice guideline summary on heart failure, its pyelonephritis and urinary tract infection reviews, its hypothyroidism review, its depression pharmacologic treatment review, and its gout reviews, used as the primary clinical resource for the class facts. FDA prescribing information on DailyMed for metformin, sulfamethoxazole-trimethoprim, flumazenil, lithium, apixaban, and amlodipine, for the labeled dosing thresholds, ranges, and boxed warnings. The 2021 IDSA guidance on Clostridioides difficile as summarized in the clinical reviews above. Full claim by claim sourcing is kept with this page’s production file and checked at every refresh.
Want more pharmacology questions like these, with a full rationale for every answer? They live inside the 650-question FNP bank in our shop.
For clinician education only — not medical advice.

Leave a Reply